Yes, endocrine therapy is absolutely needed after total mastectomy for ER-positive breast cancer.
Endocrine therapy is a standard, non-negotiable component of treatment for all patients with hormone receptor-positive breast cancer following mastectomy, as it significantly reduces distant recurrence and improves disease-free survival. 1
Treatment Duration and Options
For postmenopausal women with ER-positive breast cancer after mastectomy, you should offer one of these evidence-based regimens 1:
Initial 5-Year Treatment Options:
- Aromatase inhibitor (AI) for 5 years (anastrozole, letrozole, or exemestane)
- Tamoxifen for 5 years
- Tamoxifen for 2-3 years, then switch to AI for remainder of 5 years
Extended Therapy (Beyond 5 Years):
For node-positive disease: Extended therapy up to 10 years total is strongly recommended 1
For node-negative disease: Extended therapy should be offered based on recurrence risk using established prognostic factors. Women with low-risk node-negative tumors should NOT routinely receive extended therapy 1
The specific extended regimens include:
- AI for up to 10 years total
- Tamoxifen 5 years → AI for 5 more years (10 years total)
- Tamoxifen 2-3 years → AI for 7-8 years (up to 10 years total)
- Tamoxifen for 10 years
Critical Mastectomy-Specific Consideration
Important caveat: Women who underwent bilateral mastectomy will NOT benefit from the secondary prevention effect of extended endocrine therapy (prevention of contralateral breast cancer), which accounts for a substantial portion of the benefit. This should factor into your risk-benefit discussion about extended therapy 1. However, this does NOT negate the need for the initial 5 years of therapy, which reduces distant recurrence.
Evidence Quality
These recommendations carry high-quality evidence with strong recommendation strength from ASCO guidelines 1. Note that to date, no studies have shown overall survival improvement with extended AI therapy beyond 5 years—the benefits are in preventing distant recurrence and second breast cancers 1.
Common Pitfall to Avoid
Do not confuse this with DCIS: One study 2 showed no benefit of endocrine therapy after mastectomy for HR-positive DCIS (ductal carcinoma in situ), but your question concerns invasive breast cancer, where endocrine therapy is essential.
Shared Decision-Making for Extended Therapy
While initial 5-year therapy is mandatory, the decision to extend beyond 5 years requires weighing:
- Recurrence risk (nodal status, tumor size, grade)
- Ongoing side effects (bone loss, arthralgias, vasomotor symptoms)
- Patient tolerance and preferences 3
- Whether bilateral mastectomy was performed (reduces contralateral cancer prevention benefit)
For premenopausal women, tamoxifen remains the standard, with consideration for ovarian suppression plus AI in higher-risk cases 1.